Viking Therapeutics VKTX Operating Income
Operating Income at other companies
Other financials
Where this comes from
Reported directly by Viking Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:OperatingIncomeLoss.
The official record: Viking Therapeutics’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Viking Therapeutics's operating income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Viking Therapeutics's operating income?
- Viking Therapeutics (VKTX) reported operating income of -$164.13M in Q1 2026.
- How has Viking Therapeutics's operating income changed year-over-year?
- Viking Therapeutics's operating income decreased by 195.9% year-over-year, from -$55.47M to -$164.13M.
- What is the long-term trend for Viking Therapeutics's operating income?
- Over 4 years (2021 to 2025), Viking Therapeutics's operating income has grown at a 63.0% compound annual growth rate (CAGR), from -$55.68M to -$393.34M.
- What does operating income mean?
- Gross profit minus all operating expenses (SG&A, R&D, D&A). Measures the profit from core business operations before interest, taxes, and non-operating items.